MVGJX
Price
$18.27
Change
-$0.01 (-0.05%)
Updated
Sep 20 closing price
RWIBX
Price
$66.87
Change
-$0.15 (-0.22%)
Updated
Sep 20 closing price
Ad is loading...

MVGJX vs RWIBX

Header iconMVGJX vs RWIBX Comparison
Open Charts MVGJX vs RWIBXBanner chart's image
MFS Low Volatility Global Equity R1
Price$18.27
Change-$0.01 (-0.05%)
VolumeN/A
CapitalizationN/A
American Funds Capital World Gr&Inc R2
Price$66.87
Change-$0.15 (-0.22%)
VolumeN/A
CapitalizationN/A
View a ticker or compare two or three
MVGJX vs RWIBX Comparison Chart
Loading...
VS
MVGJX vs. RWIBX commentary
Sep 21, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MVGJX is a Buy and RWIBX is a StrongBuy.

FUNDAMENTALS
Fundamentals
RWIBX has more cash in the bank: 128B vs. MVGJX (279M). RWIBX pays higher dividends than MVGJX: RWIBX (1.05) vs MVGJX (0.43). MVGJX was incepted earlier than RWIBX: MVGJX (11 years) vs RWIBX (22 years). RWIBX is a more actively managed with annual turnover of: 27.00 vs. MVGJX (25.00). MVGJX has a lower initial minimum investment than RWIBX: MVGJX (0) vs RWIBX (250). RWIBX (23.75) and MVGJX (23.37) have marching annual gain over last year. RWIBX return over 5 years is better than : 42.68 vs. MVGJX (34.34).
MVGJXRWIBXMVGJX / RWIBX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence11 years22 years-
Gain YTD16.49913.562122%
Front LoadN/AN/A-
Min. Initial Investment0250-
Min. Initial Investment IRAN/AN/A-
Net Assets279M128B0%
Annual Yield % from dividends0.431.0541%
Returns for 1 year23.3723.7598%
Returns for 3 years11.697.37159%
Returns for 5 years34.3442.6880%
Returns for 10 years83.5949.04170%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GNFT4.940.75
+17.90%
Genfit SA
NNI112.94-2.01
-1.75%
Nelnet
ILMN131.14-3.25
-2.42%
Illumina
SPRB0.44-0.01
-2.59%
Spruce Biosciences
APLT7.70-0.30
-3.75%
Applied Therapeutics